Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous
anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis,
which is a fungus infection of the blood or tissue. Currently the drug is approved for
treatment using a daily dose of IV medication until 14 days after the fungus disappears from
the blood. This study will evaluate the effectiveness of intravenous anidulafungin when it
is administered for 5-28 days followed by oral antifungal medication. Study patients will be
assessed for response to treatment throughout the study drug treatment period.
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
This study compares the effectiveness and safety of the combination of anidulafungin and
voriconazole compared to that of voriconazole alone (which is generally considered the
standard of care) for the treatment of Invasive Aspergillosis.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.